Cognitive Rehabilitation in Sickle Cell Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01793740|
Recruitment Status : Completed
First Posted : February 18, 2013
Last Update Posted : August 20, 2014
|Condition or disease||Intervention/treatment|
|Sickle Cell Disease Cognitive Impairment||Behavioral: Cogmed|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Cognitive Rehabilitation of Children With Sickle Cell Disease: A Pilot Study|
|Study Start Date :||October 2012|
|Primary Completion Date :||July 2014|
|Study Completion Date :||July 2014|
These children are enrolled in the Cogmed intervention.
Computer based program that aims to improve children's memory, attention, and processing speed.
Other Name: Cogmed computerized cognitive training
No Intervention: Waitlist
These children are enrolled in a waitlist condition, after which they will be offered the opportunity to complete the intervention.
- Feasibility [ Time Frame: Post-study - Baseline to Post-Intervention, approximately 5 to 8-weeks after baseline assessment ]Feasibility is defined as 75% of subjects completing 80% of the training program.
- Efficacy [ Time Frame: Baseline to Post-Intervention, approximately 5 to 8-weeks after baseline assessment ]Efficacy will be defined by participant performance on cognitive outcome measures including executive functioning outcomes from the Cogstate.
- Acceptance [ Time Frame: After the recruitment period has been completed (approximately 2-years) ]Acceptance is defined by 50% of those approached are able to participate/consent to the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01793740
|United States, North Carolina|
|Duke Child and Family Study Center|
|Durham, North Carolina, United States, 27705|
|Principal Investigator:||Melanie J Bonner, PhD||Duke University|